Literature DB >> 35854166

Renal response and its predictive factors of lupus nephritis: a 2-year real-world study of 56 hospital-based patients.

Keqian Du1, Xuecheng Zhang2, Junmei Feng3, Sijie Zhong1, Jun Qi4, Zhiming Lin5.   

Abstract

OBJECTIVES: Our aim was to evaluate the renal response rate of patients with lupus nephritis (LN) undergoing standard treatment during a 2-year follow-up and to investigate its predictive factors.
METHODS: A prospective cohort study that enrolled 56 clinically diagnosed LN patients with urinary protein positivity was carried out. All patients underwent standard treatment. All patients were followed up at 6-month intervals for 2 years. Data on renal response and clinical characteristics were collected and analyzed.
RESULTS: Among 56 patients, 27 (48.2%) and 13 (23.2%) patients achieved complete renal response (CR) and partial renal response (PR) at 6 months after induction therapy, respectively, and 42 (75.0%) and 4 (7.1%) patients developed CR and PR at 2 years. Among patients who achieved PR at 6 months, 90.0% achieved CR at 24 months, while only 37.5% of the patients who were unresponsive at 6 months achieved CR. In the multivariable Cox proportional-hazards model, female (OR 6.51, 95% CI 1.23-34.52, p = 0.028), disease duration (OR 0.84, 95% CI 0.73-0.98, p = 0.021), achieving PR within 6 months (OR 8.09, 95% CI 2.06-31.73, p = 0.003), and urine protein/creatinine ratio (UPCR) (OR 0.998, 95% CI 0.996-1.000, p = 0.025) were found to be predictive factors of CR.
CONCLUSION: A total of 48.2% of patients achieved CR at 6 months of induction therapy, and the response rates gradually increased to 60.7%, 64.3%, and 75.0% at 12, 18, and 24 months. Besides, female, disease duration, partial response within 6 months, and UPCR were predictive factors for a complete renal response. Key Points • We evaluate the renal response rates in Chinese patients with lupus nephritis in the real world for 2 years. • A total of 48.2% and 75.0% of patients achieved a complete response after standard treatment for 6 months and 2 years. • Female, disease duration, partial response within 6 months, and UPCR are predictors of complete renal response.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Lupus nephritis; Renal response rate; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2022        PMID: 35854166     DOI: 10.1007/s10067-022-06258-0

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   3.650


  22 in total

Review 1.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.

Authors:  Feng Yu; Mark Haas; Richard Glassock; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

2.  Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis.

Authors:  Julie E Davidson; Qinggong Fu; Beulah Ji; Sapna Rao; David Roth; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2018-03-01       Impact factor: 4.666

3.  Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.

Authors:  Chi Chiu Mok; King Yee Ying; Cheuk Wan Yim; Yui Pong Siu; Ka Hang Tong; Chi Hung To; Woon Leung Ng
Journal:  Ann Rheum Dis       Date:  2014-12-30       Impact factor: 19.103

4.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

Review 5.  Current and Emerging Therapies for Lupus Nephritis.

Authors:  Samir V Parikh; Brad H Rovin
Journal:  J Am Soc Nephrol       Date:  2016-06-09       Impact factor: 10.121

Review 6.  Lupus nephritis: challenges and progress.

Authors:  Anne Davidson; Cynthia Aranow; Meggan Mackay
Journal:  Curr Opin Rheumatol       Date:  2019-11       Impact factor: 5.006

Review 7.  Induction Therapy for Lupus Nephritis: the Highlights.

Authors:  Isabelle Ayoub; Jessica Nelson; Brad H Rovin
Journal:  Curr Rheumatol Rep       Date:  2018-08-14       Impact factor: 4.592

8.  Comparison of renal response to four different induction therapies in Japanese patients with lupus nephritis class III or IV: A single-centre retrospective study.

Authors:  Hironari Hanaoka; Tomofumi Kiyokawa; Harunobu Iida; Kana Ishimori; Yukiko Takakuwa; Takahiro Okazaki; Hidehiro Yamada; Daisuke Ichikawa; Sayuri Shirai; Junki Koike; Shoichi Ozaki
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

9.  Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV.

Authors:  Hironari Hanaoka; Hidehiro Yamada; Tomofumi Kiyokawa; Harunobu Iida; Takeshi Suzuki; Yoshioki Yamasaki; Seido Ooka; Hiroko Nagafuchi; Takahiro Okazaki; Daisuke Ichikawa; Sayuri Shirai; Yugo Shibagaki; Junki Koike; Shoichi Ozaki
Journal:  Arthritis Res Ther       Date:  2017-01-13       Impact factor: 5.156

10.  Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Authors:  George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas
Journal:  Ann Rheum Dis       Date:  2012-07-31       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.